Wharton's jelly derived mesenchymal stem cells: future of regenerative medicine? Recent findings and clinical significance

Biomed Res Int. 2015;2015:430847. doi: 10.1155/2015/430847. Epub 2015 Mar 15.

Abstract

Around 5 million annual births in EU and 131 million worldwide give a unique opportunity to collect lifesaving Wharton's jelly derived mesenchymal stem cells (WJ-MSC). Evidences that these cells possess therapeutic properties are constantly accumulating. Collection of WJ-MSC is done at the time of delivery and it is easy and devoid of side effects associated with collection of adult stem cells from bone marrow or adipose tissue. Likewise, their rate of proliferation, immune privileged status, lack of ethical concerns, nontumorigenic properties make them ideal for both autologous and allogeneic use in regenerative medicine applications. This review provides an outline of the recent findings related to WJ-MSC therapeutic effects and possible advantage they possess over MSC from other sources. Results of first clinical trials conducted to treat immune disorders are highlighted.

Publication types

  • Review

MeSH terms

  • Adipose Tissue / physiology
  • Adult Stem Cells / physiology
  • Animals
  • Cell Proliferation / physiology
  • Humans
  • Mesenchymal Stem Cells / physiology*
  • Regenerative Medicine / methods
  • Wharton Jelly / physiology*